Here's What You Don't Know About Merck & Co. Inc., Today's Best Dow Stock

One of the world's largest pharmaceutical companies also has one of the world's most storied corporate lineages.

Apr 29, 2014 at 12:10PM

The Dow Jones Industrial Average (DJINDICES:^DJI) is off to a solid start in April's final week, and its pharmaceutical components have been major contributors. Pfizer (NYSE:PFE) paced Monday's index gain as it pursued another megabuyout, and today's pop is led by Merck (NYSE:MRK), which is the only one of 30 Dow components to post a gain markedly greater than 1% in early afternoon trading. Investors are cheering the pharmaceutical giant's first-quarter earnings, which beat Wall Street's expectations on the bottom line despite looking somewhat soft on the top.

You probably know a fair bit about Merck, one of the world's largest pharmaceutical companies -- it ranked seventh globally in 2013 revenue on a list that included several competitors with more diverse health-care offerings, and sixth in market cap on the same list -- but how much do you know about the path Merck has taken to become one of the Dow's two pharmaceutical specialists? The company's long history might surprise you. And it is a long history.

Merck traces its origins to 1668, when Friedrich Jacob Merck bought the "Angel Apothecary" in Germany. Apothecaries were pharmacies in the pre-pharmaceutical era, and Merck established his family name in the drugs-and-chemicals business from the very beginning, although it would take over two centuries to expand from Germany to the United States. Merck finally established a subsidiary in New York in 1891, but it only operated as part of the German parent until World War I, when Berlin's aggression prompted the U.S. government to seize German-owned companies and subsidiaries.

The new Merck, reestablished under American ownership, was one of the two most important companies at the start of the modern pharmaceutical industry. Merck was the first company to mass-produce penicillin in 1942; in the 80 years following its first dosage, Merck's shares grew by 9.7% per year, before factoring in the compounding effect of dividend reinvestment.

Four years after it began manufacturing penicillin, Merck's shares left over-the-counter trading and began trading on the New York Stock Exchange. Despite its role in penicillin production, Merck was still primarily a chemicals company, but its enhanced share status gave it the legitimacy needed to merge with pioneering pharmaceutical company Sharp & Dohme in 1953. This new Merck -- which is known as MSD, or Merck Sharpe & Dohme in the rest of the world -- soon became a leader in drug development under the guidance of Maurice Hilleman, who has been credited with saving more lives (thanks to the development of new vaccines) than any other 20th-century scientist.

Merck is known as MSD elsewhere in the world to avoid confusion with the original German Merck, which still does business in the same town where Friedrich Jacob Merck established his family drug business in 1668. The German Merck, which is known as EMD Millipore in the United States, is also a major global pharmaceutical company, but the American Merck outweighs it easily by revenue -- Germany's Merck earned about $15.3 billion in 2013, but America's Merck earned over $44 billion that year. 

Merck joined the Dow in 1979 as its first health-care component, and it has vastly outperformed the index ever since. However, only when dividend reinvestment is factored in (total return) does Merck truly shine, as you can see:

MRK Chart

MRK data by YCharts.

Merck is also a leading medical publisher, issuing medical reference books since the 1889 first release of The Merck Index, a compendium of drugs and chemicals. Since then, Merck has branched out to publish books of diseases and symptoms for physicians and medical students (The Merck Manual, since 1899), an animal health care manual (The Merck Veterinary Manual, since 1955), and a health-care compendium focused on elder care (The Merck Manual of Geriatrics, since 1990). Its Merck Manual is the world's best-selling medical textbook.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Alex Planes holds no financial position in any company mentioned here. Add him on Google+ or follow him on Twitter @TMFBiggles for more insight into markets, history, and technology.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information